Simvastatin (Zocor)

A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.

Also Known As:

Networked: 3176 relevant articles (350 outcomes, 1053 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Pedersen, Terje R: 35 articles (11/2015 - 01/2003)
2.	Wachtell, Kristian: 30 articles (12/2015 - 04/2007)
3.	Gerdts, Eva: 29 articles (11/2015 - 04/2007)
4.	Ray, Simon: 24 articles (12/2015 - 04/2007)
5.	Boman, Kurt: 23 articles (12/2015 - 04/2007)
6.	Rossebø, Anne B: 21 articles (11/2015 - 04/2007)
7.	Kastelein, John J P: 21 articles (08/2010 - 07/2002)
8.	Ballantyne, Christie M: 20 articles (11/2015 - 11/2003)
9.	Tershakovec, Andrew M: 20 articles (10/2015 - 10/2006)
10.	Cramariuc, Dana: 18 articles (11/2015 - 02/2008)

Related Diseases

1.	Hypercholesterolemia 06/01/2010 - "Our findings support claims that simvastatin may be beneficial in preserving endothelial function in prediabetic subjects with normo- or mild-to-moderate hypercholesterolemia. " 10/16/1989 - "Simvastatin appears to be an effective and well-tolerated agent for the treatment of primary hypercholesterolemia and, as further study confirms long-term safety and efficacy, it should become a useful addition to the therapeutic armamentarium." 12/01/1999 - "Simvastatin therapy for 12 months is well tolerated and effective for both women and men with hypercholesterolemia. " 05/01/1997 - "We found that low-dose simvastatin therapy is effective in achieving long-term decreases in serum lipid levels and is well tolerated by patients with moderate hypercholesterolemia. " 11/01/1995 - "They further indicate that once-daily treatment with simvastatin is effective in patients with isolated hypercholesterolemia or hypercholesterolemia associated with elevated triglyceride levels."
2.	Hyperlipidemias (Hyperlipidemia) 06/01/2009 - "In the short-term the combination of diet and simvastatin was effective in lowering hyperlipidemia in children with renal disorders." 03/01/2004 - "Simvastatin was an effective and generally well tolerated treatment for hyperlipidemia when used in combination with TZD therapy in this population of patients with type 2 DM." 03/01/2015 - "The study performed to evaluate the efficacy of Nigella sativa in comparison to simvastatin to treat hyperlipidemia. " 05/01/2008 - "This study suggests for the first time that simvastatin treatment in diabetic patients with hyperlipidemia is associated with an improvement in the heterogeneity of cardiac repolarization. " 03/01/2015 - "Simvastatin is a synthetic lipid lowering drug and Nigella sativa seeds found helpful in controlling hyperlipidemia. "
3.	Dyslipidemias (Dyslipidemia) 02/01/2009 - "These results suggest non-HDL-C, TG (both 50% to 60%), and HDL-C (∼25%) concentrations can be markedly improved by a combination of P-OM3 (4 g/day) and simvastatin (80 mg/day) in subjects with mixed dyslipidemia." 02/01/2008 - "Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia." 08/01/2014 - "A total of 102 patients with dyslipidemia were treated with simvastatin or placebo during a double-blind, cross-over, placebo-controlled trial. " 03/01/2014 - "Effect of Nigella sativa and Allium sativum coadminstered with simvastatin in dyslipidemia patients: a prospective, randomized, double-blind trial." 09/01/2013 - "This study was designed to compare the efficacy and tolerability of morning and evening doses of controlled-release simvastatin in Korean adults with dyslipidemia. "
4.	Atherosclerosis 05/01/1991 - "The results indicate that simvastatin would be effective in the treatment of atherosclerosis." 01/01/2013 - "The present study tested whether simvastatin, as a prototype statin, enhances autophagy in coronary arterial myocytes (CAMs) to thereby exert their beneficial effects in atherosclerosis. " 02/01/2009 - "The aim of this study was to investigate the expression and localization of sPLA2 IIa in atherosclerosis of rat aorta, myocardium and visceral adipose tissue (VAT) and to explore the effect of simvastatin on sPLA2 IIa expression. " 02/04/2004 - "The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging." 12/05/2000 - "In the present study, we report that simvastatin reduces endothelial barrier dysfunction, which is associated with the development of atherosclerosis. "
5.	Inflammation 12/26/2010 - "In conclusion, in hyperlipidemic HD patients, simvastatin treatment resulted in a significant reduction in markers of endothelial dysfunction, inflammation, oxidative stress, endothelial cell apoptosis and peripheral blood monocyte stimulation. " 02/01/2007 - "Simvastatin improved endocrine/clinical aspects of PCOS and had beneficial effects on lipid profile and markers of systemic inflammation." 03/01/2012 - "The addition of simvastatin to the storage solution, maintained KLF2-dependent vasoprotective programs, prevented liver damage, inflammation, and oxidative stress and improved endothelial dysfunction. " 11/01/2008 - "These results suggest that simvastatin ameliorates I/R-induced liver and lung tissue damage by inhibiting the level of inflammation and the apoptotic pathways. " 06/01/2003 - "Moreover, aggressive lipid-lowering therapy with simvastatin does not result in improved endothelial function or in a reduction of markers of inflammation in these patients."

Related Drugs and Biologics

1.	atorvastatin (Lipitor)
2.	ezetimibe (Zetia)
3.	Cholesterol
4.	Pravastatin (Pravachol)
5.	LDL Cholesterol
6.	rosuvastatin (Crestor)
7.	Lovastatin (Mevacor)
8.	Fenofibrate (CiL)
9.	Lipoproteins (Lipoprotein)
10.	simvastatin drug combination ezetimibe (Vytorin)

Related Therapies and Procedures

1.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
2.	Drug Therapy (Chemotherapy)
3.	Renal Dialysis (Hemodialysis)
4.	Transplantation (Transplant Recipients)
5.	Ligation